Imaging Agent Granted FDA Fast Track Designation
FluoGuide A/S announced that the U.S. FDA has granted Fast Track designation to its intraoperative imaging agent FG001, targeting high‑grade glioma surgery. The designation recognizes the serious nature of glioblastoma and the agent's promise to improve tumor visualization during resection. Fast Track status gives FluoGuide earlier FDA interaction, eligibility for rolling review, and potential pathways to Accelerated Approval and Priority Review. The company plans to start a Phase 2 registration trial in the United States in Q2 2026.
Quotient Therapeutics & Merck Enter ~$2.2B Partnership to Discover Novel Drug Targets in IBD
Quotient Therapeutics and Merck have signed a multi‑year collaboration to use Quotient’s somatic genomics platform for discovering new drug targets in inflammatory bowel disease. The agreement provides Quotient with $20 million upfront and includes milestone payments that could lift the total...
Radiopharmaceutical Clinical Trials in 2026: How to De-Risk Isotope Supply, Imaging Variability, and Regulatory Pathways
Radiopharmaceutical clinical trials are becoming a high‑velocity segment in 2026, but they remain vulnerable to three predictable bottlenecks: isotope supply chain fragility, imaging variability, and regulatory pathway selection. Axcellant, a boutique CRO with an integrated imaging core lab, demonstrates that...
Synthetic DNA Manufacturing Hub Set Up in Boston by Artis BioSolutions
Artis BioSolutions, a San Diego‑based advanced therapies firm, has launched a synthetic DNA manufacturing hub in Boston using Syngoi Technologies' proprietary enzymatic platform. The new site complements its GMP manufacturing facility in Watertown, creating a bi‑continental network with an existing...
Biotech Investors Set to Meet with Key Congressional Panel
A bipartisan congressional commission focused on maintaining U.S. leadership in biotechnology will host a meeting with leading biotech investors next week. The investors, representing venture capital firms and industry funds, aim to discuss policy gaps, funding mechanisms, and regulatory hurdles....
Prestige Biopharma Reports Topline P-III (SAMSON-II) Study Results for HD204 (Biosimilar, Avastin)
Prestige Biopharma announced topline results from its phase‑III SAMSON‑II trial comparing HD204, a biosimilar to Avastin (bevacizumab), with the reference product in 625 patients with advanced non‑squamous non‑small cell lung cancer. The study demonstrated an objective response rate (ORR) of...
Apnimed Set to Exit Sleep Disorder Joint Venture with Shionogi for $100M Upfront
Japanese pharmaceutical company Shionogi is buying out Apnimed’s 50% stake in their sleep‑disorder joint venture for an upfront payment of $100 million. The acquisition gives Shionogi full control over the partnership’s pipeline, which focuses on treatments for conditions such as obstructive...
E Fund HK Launches “Global First” Biotech ETF Bridging Hong Kong and US Markets
E Fund Management Hong Kong launched the E Fund (HK) Solactive Biopharma Select Index ETF (code 3186) on March 23, 2026, the first ETF to blend Hong Kong and US biotech stocks. The index tracks up to 100 biotechnology and pharmaceutical firms, weighting...
Clemastine Fumarate Activates Lipophagy to Promote Oligodendrocyte Progenitor Cells Differentiation and Remyelination in a Cuprizone-Induced Demyelination Model
Researchers discovered that clemastine fumarate activates lipophagy in oligodendrocyte progenitor cells (OPCs), clearing lipid droplets that impede differentiation. In vitro, the drug enhanced OPC maturation and removed myelin debris, while in a cuprizone‑induced mouse model it restored myelin integrity and...
Dietary Fructo-Oligosaccharides Dose-Dependently Modulate the Microbiome and Suppress Type 2 Lung Inflammation in a Murine Model of House Dust Mite-Induced...
Researchers fed BALB/c mice diets containing 1 %, 2.5 %, 5 %, or 10 % fructo‑oligosaccharides (FOS) before and during house‑dust‑mite sensitisation. While overall eosinophil recruitment to the lungs was unchanged, FOS dose‑dependently lowered lung Th2 cell frequencies and reduced key type 2 cytokines such...
Ecnoglutide Approval Intensifies Competition in China GLP-1 Obesity Market
China's National Medical Products Administration approved Sciwind Biosciences' Ecnoglutide injection, marking the country's fifth GLP‑1 obesity therapy. The drug demonstrated a 15.4% average weight loss in the Phase III SLIMMER trial, with over 90% of participants achieving at least 5%...
Accumulus Technologies Launches the Accumulus Connector, Delivering Live Integration Across Regulatory Systems
Accumulus Technologies launched the Accumulus Connector, extending its platform into customers’ existing pharma and biotech systems for live, bi‑directional regulatory communication. The Connector provides real‑time, one‑click global submissions to more than 70 national regulators, eliminating manual data reconciliation. By integrating...
China Approves World’s First Implantable BCI
China's National Medical Products Administration has granted approval for the world's first commercially available implantable brain‑computer interface (BCI). Developed by Shanghai's Borui Kang Medical Technology, the system uses implanted electrodes to translate neural signals into commands for an assistive glove,...
New Zealand Begins Genomics Testing Pilot and More Briefs
Te Whatu Ora Health New Zealand launched a two‑year genomics testing pilot with Illumina, targeting over 6,000 cancer and rare‑disease samples. The initiative seeks to localise roughly half of the 4,000 tests currently sent abroad, cutting the current $2.3 million annual overseas...
Can a Mouse Be Cloned Indefinitely? Decades-Long Experiment Has Answers
Researchers at the University of Yamanashi completed a two‑decade experiment that serially cloned a single mouse for 58 generations before the process failed. Over 30,000 cloning attempts revealed that large‑scale DNA mutations, including loss of an entire chromosome, accumulated in...
Anesthetics as Emerging Therapeutics for Post-Traumatic Stress Disorder (PTSD): Bridging Bench and Bedside
A recent Molecular Psychiatry review highlights anesthetics as a promising new class of therapeutics for post‑traumatic stress disorder (PTSD). It outlines how NMDA‑receptor antagonists, α2‑adrenergic agonists, GABA‑A modulators and certain opioids can modulate fear circuitry and memory reconsolidation. Pre‑clinical models...
UCSF and Biohub Scientists Develop New Material to Grow More Consistent Lab Organs
Scientists at UCSF and the Biohub have engineered a seaweed‑derived alginate‑Matrigel composite that behaves like wet sand, enabling precise 3D bioprinting of stem cells. The material’s stress‑relaxation properties allow printed cells to stay positioned while the tissue self‑organizes, producing organoids...
HIV Remains Suppressed in Some Patients After Treatment Withdrawal
Scientists at Gladstone Institutes identified two host genes, DDIT4 and ZNF254, that act as molecular locks keeping HIV dormant after antiretroviral therapy (ART) cessation. Multi‑omic analysis of 75 participants from analytical treatment interruption trials linked higher expression of these genes,...
MRI-Guided Ablation as Effective as Surgery for Prostate Cancer Treatment
MRI‑guided TULSA ablation matches or exceeds robotic radical prostatectomy for intermediate‑risk prostate cancer. In the CAPTAIN trial of 211 patients, TULSA halved rates of erectile dysfunction and urinary incontinence, eliminated blood loss, and shortened hospital stays. Functional recovery was faster,...
Market Shifts Powering the Growth of Sterile Injectable Manufacturing
The sterile injectable contract manufacturing market is rapidly evolving as demand surges for both large‑scale biologics and niche, small‑batch therapies. Leading CDMOs are responding by expanding production capacity, building global redundancy, and investing heavily in specialized talent. Development and pre‑commercial...
Skin Regeneration Enabled by Embryonic Healing Mechanism in Mice
Harvard researchers published a Cell study showing that mouse skin can fully regenerate by reactivating an embryonic healing program that normally shuts down after birth. They identified excessive nerve growth—hyperinnervation—driven by fibroblast‑derived Cxcl12 as the key barrier to regeneration. Genetic...
Study Makes Promising Advances in Accurately Diagnosing Sepsis
Doctors at Liverpool and Cardiff University, together with 20 NHS hospitals, completed a large randomized trial of a rapid procalcitonin‑guided algorithm for suspected sepsis. The study of 7,667 emergency patients showed a 17% relative drop in mortality—from 16.6% to 13.6%—equating...
Bariatric Surgery in Adolescents 'Reprograms' Kidney Biology to Promote Recovery
A multi‑institutional study in the Journal of Clinical Investigation shows that vertical sleeve gastrectomy in adolescents with type 2 diabetes and obesity triggers profound molecular reprogramming of kidney cells, leading to functional recovery. Over a 12‑month follow‑up, participants lost weight, improved...
New Tongue-Swab TB Test Could Help Eradicate The Disease, WHO Says
The World Health Organization has endorsed a new near‑point‑of‑care molecular test that uses a simple tongue swab to detect tuberculosis in under an hour. Developed by PlusLife on its MiniDock platform, the device costs up to 90% less than GeneXpert...
Timeline of Selected FDA Activities and Significant Events Addressing Substance Use and Overdose Prevention
Since 1995 the FDA has moved from approving standard opioid products to implementing a comprehensive regulatory regime aimed at curbing misuse and overdose. Key milestones include the 2007 authority to require Risk Evaluation and Mitigation Strategies (REMS), a series of...
CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) Initiative
The FDA’s Center for Drug Evaluation and Research (CDER) launched the Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) to create a regulatory pathway for emerging manufacturing technologies. FRAME focuses on four priority technologies—end‑to‑end continuous manufacturing, distributed manufacturing (including non‑traditional sites),...
More Data Support Investigational Drug Combo for HIV Therapy
Phase 3 data presented at the 2026 Conference on Retroviruses and Opportunistic Infections show that the doravirine‑islatravir (DOR/ISL) two‑drug regimen met non‑inferiority criteria versus the standard bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) triple‑pill. At week 48, 91.8% of participants on DOR/ISL achieved viral suppression compared...
BTK Inhibition in CLL: Comparing Brukinsa and Jaypirca Approaches
BTK inhibitors have become the cornerstone of chronic lymphocytic leukemia therapy, replacing traditional chemotherapy. Brukinsa (zanubrutinib) is a second‑generation irreversible inhibitor that offers high selectivity and strong efficacy in treatment‑naïve or early‑relapse patients, with reduced cardiovascular risk. Jaypirca (pirtobrutinib) is...
FDA Drug Safety Communication: Safety Review Update of Recombinant Human Growth Hormone (Somatropin) and Possible Increased Risk of Death
The FDA updated its safety review of recombinant human growth hormone (somatropin) after the French SAGhE study raised concerns about a possible increased risk of death. The agency identified significant design flaws in the study and found no supporting evidence...
When Doctors Prescribe Horoscopes: The Trouble With Biological Age Tests
Consumer epigenetic "biological age" tests promise a single number that reflects a person’s true health trajectory, but they actually measure DNA methylation patterns correlated with chronological age. Research‑grade clocks can predict mortality risk, yet the kits sold to patients lack...
Tang Seizes Control of Aurinia, Taking CEO Post in Total Transformation of C-Suite
Kevin Tang, chair of Aurinia’s board and head of Tang Capital Management, has seized the CEO role, replacing Peter Greenleaf, and installed fellow Tang Capital executives as COO, CFO, and CSO. Tang Capital expanded its ownership from 5.1% in September 2024 to 9.2%...
Stock Movers: Apogee, Synopsys, Norwegian Cruise (Podcast)
Apogee Therapeutics' shares jumped after the company released mid‑stage trial data showing its experimental drug deepened responses in patients with moderate‑to‑severe atopic dermatitis. Synopsys rose as activist investor Elliott Investment Management disclosed a multibillion‑dollar investment in the chip‑design software firm....
Rheumatology Enters the Gut-Brain-Immune Axis
Healio’s latest editorial highlights the expanding role of GLP‑1 receptor agonists in immune‑mediated inflammatory diseases, emphasizing weight‑independent anti‑inflammatory mechanisms. Emerging data suggest central nervous system GLP‑1 activation can modulate peripheral immunity, linking the gut‑brain‑immune axis. The FDA’s recent approval of...
New Hope For Spina Bifida
A new prenatal therapy combining in‑utero surgery with placental stem‑cell patches, tested in the CuRe trial, has shown promising safety results for spina bifida. Six pregnancies underwent the procedure between 19 and 26 weeks, all delivering without infection, fluid leak,...
The Six Biotech Companies in Portugal You Should Know About in 2026
Portugal’s biotech sector is gaining momentum, highlighted by BIO‑Europe Spring in Lisbon. Six home‑grown companies—Beat Therapeutics, BSIM Therapeutics, Exogenus, Immunethep, Mondego Bio and TechnoPhage—are advancing novel therapies ranging from DDR inhibitors for pancreatic cancer to exosome‑based wound treatments and bacteriophage...
CLL/SLL Treatment Choices Based on Various Factors
A population‑based study of 148 first‑line CLL/SLL patients in Alberta found that time‑limited venetoclax‑obinutuzumab was used in 51% of cases, while continuous BTK inhibitor therapy accounted for 44%. Patients with del(17p) or TP53 mutations chose BTK inhibitors in 84% of...
FDA Warns of Seizure Risk with some Parkinson’s Drugs
The FDA’s recent safety alert warns that high‑dose levodopa/carbidopa regimens can provoke seizures when patients develop vitamin B6 deficiency. Fourteen post‑marketing cases, including two fatalities, involved doses exceeding 1,000 mg daily and featured focal‑onset seizures that generalized. Vitamin B6 supplementation halted...
Kali Therapeutics Partners with Sanofi for KT501 in a ~$1.2B Deal
Kali Therapeutics has signed a license agreement with Sanofi granting the French giant exclusive worldwide rights to KT501, a next‑generation tri‑specific T‑cell engager aimed at B‑cell‑mediated autoimmune diseases. The deal provides Kali with $180 million in upfront and near‑term payments and...
Henlius Receives NMPA IND Clearance for HLX18 (Biosimilar, Opdivo)
Henlius announced that China’s National Medical Products Administration (NMPA) has granted IND clearance for HLX18, a biosimilar of Opdivo (nivolumab), targeting resected solid tumours. The company also reported first‑patient dosing in Phase I trials for HLX17 (Keytruda biosimilar) and HLX13...
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
Xilio Therapeutics reported a strong cash position of $137.5 million, extending its runway to the end of 2027, and highlighted significant pipeline advances. The company plans to file an IND for its bispecific PD‑1/masked IL‑2 candidate XTX501 in mid‑2026 and start...
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma announced a $950 million upfront settlement from Moderna, with a potential $1.3 billion contingent payment, strengthening its cash position to $91.5 million. The company reported $14.1 million revenue for 2025, driven by license milestones, while cutting R&D expenses by $28.8 million. Clinical progress...
Viruses in the Gut May Help Prevent Blood Sugar Spikes, Mouse Study Hints
A mouse study published in Cell Host & Microbe shows that the gut virome—primarily bacteriophages—modulates carbohydrate metabolism by activating immune pathways. Disrupting the virome with an antiviral cocktail caused sharp blood‑glucose spikes in mice fed a high‑carbohydrate diet, while enriching...
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Pyxis Oncology announced completion of target enrollment for its Phase 1 MICVO monotherapy study in recurrent/metastatic head and neck cancer, enrolling roughly 40 patients. Interim CEO Thomas Civik highlighted promising early efficacy, with a 46% objective response rate as monotherapy and a...
STAT+: Insmed Drug Benefits Patients with Rare, Bacterial Lung Disease, Study Shows
Insmed announced that a Phase 3 trial showed adding its inhaled antibiotic Arikayce to standard therapy significantly improved respiratory symptoms and boosted culture conversion rates in patients with newly diagnosed mycobacterium avium complex (MAC) lung infection. The study met its primary...
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
Avalo Therapeutics announced its 2025 financial results, reporting $98.3 million in cash and short‑term investments that should fund operations into 2028. Research and development expenses jumped to $50.1 million, driven by the Phase 2 LOTUS trial of abdakibart (AVTX‑009) for hidradenitis suppurativa. The...
